Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis With Prior exposure to JAK1/2 Inhibitors

The impact of JAK1/2 inhibitor therapy prior to allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitor...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Biol Blood Marrow Transplant
Main Authors: Shanavas, Mohamed, Popat, Uday, Michaelis, Laura C, Fauble, Veena, McLornan, Donal, Klisovic, Rebecca, Mascarenhas, John, Tamari, Roni, Arcasoy, Murat O, Davies, James, Gergis, Usama, Ukaegbu, Oluchi C, Kamble, Rammurti T, Storring, John M, Majhail, Navneet S, Romee, Rizwan, Verstovsek, Srdan, Pagliuca, Antonio, Vasu, Sumithira, Ernst, Brenda, Atenafu, Eshetu G, Hanif, Ahmad, Champlin, Richard, Hari, Paremeswaran, Gupta, Vikas
פורמט: Artigo
שפה:Inglês
יצא לאור: 2015
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5030817/
https://ncbi.nlm.nih.gov/pubmed/26493563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.10.005
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים